Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Commentary|Articles|June 18, 2025
Hematologists Highlight Notable Insights From the 2025 EHA Congress
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.
Advertisement
Advertisement
The
Related to this article
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.
Advertisement
Advertisement